Wegovy (Semaglutide 2.4 mg): Dosing, Cost, and What to Expect

Wegovy: A Complete Patient Guide

Wegovy (semaglutide 2.4 mg) is an FDA-approved prescription medication for chronic weight management. Manufactured by Novo Nordisk, it was approved by the FDA on **June 4, 2021** for adults with obesity or overweight with weight-related conditions.

Who Is Eligible for Wegovy?

Per the FDA-approved labeling, Wegovy is indicated for adults with:

Wegovy must be used in conjunction with a reduced-calorie diet and increased physical activity.

Additionally, as of March 2024, Wegovy is indicated to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight, based on the SELECT trial results.

How It Works

Wegovy contains semaglutide, a GLP-1 (glucagon-like peptide-1) receptor agonist. It mimics a natural hormone produced in the gut that:

Dosing Schedule

Wegovy uses a gradual dose-escalation schedule to minimize side effects:

| Weeks | Dose |

|-------|------|

| Weeks 1-4 | 0.25 mg weekly |

| Weeks 5-8 | 0.5 mg weekly |

| Weeks 9-12 | 1.0 mg weekly |

| Weeks 13-16 | 1.7 mg weekly |

| Week 17 onward | 2.4 mg weekly (maintenance dose) |

The medication is self-administered as a weekly subcutaneous injection using a prefilled pen.

Side Effects

From the STEP 1 clinical trial and FDA prescribing information, the most commonly reported side effects at the 2.4 mg dose were:

| Side Effect | Wegovy | Placebo |

|------------|--------|---------|

| Nausea | 44% | 16% |

| Diarrhea | 30% | 16% |

| Vomiting | 24% | 6% |

| Constipation | 24% | 10% |

| Abdominal pain | 20% | 11% |

| Headache | 14% | 13% |

| Fatigue | 11% | 5% |

Most gastrointestinal side effects are mild to moderate and tend to decrease during continued treatment. About 7% of participants in clinical trials discontinued treatment due to gastrointestinal side effects.

**Serious warnings:** Wegovy carries a boxed warning regarding thyroid C-cell tumors observed in animal studies. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Cost

Wegovy's manufacturer list price is approximately **$1,349 per month** without insurance. Insurance coverage varies significantly by plan. Many commercial plans cover Wegovy with prior authorization, though copays can range from $25 to $300+ per month. Novo Nordisk offers a savings program for eligible commercially insured patients.

Expected Results

Based on the STEP 1 trial (NEJM 2021):

The STEP 5 trial (Nature Medicine 2022) confirmed that weight loss was maintained over 2 years of continued treatment, with 15.2% average weight loss at 104 weeks.

*Wegovy requires a prescription from a licensed healthcare provider. This guide is for educational purposes and does not replace medical advice.*